People channel feed

Trump’s ‘rad­i­cal’, ‘hor­ri­ble’ ex­ec­u­tive or­ders on drug pric­ing earn a C-suite back­lash this week — with one threat to do more over­seas

5 years ago
Bioregnum
Coronavirus

Brigham and Wom­en's pres­i­dent Eliz­a­beth Nabel fol­lows Mon­cef Slaoui off Mod­er­na's board

5 years ago
Coronavirus

Af­ter Big Phar­ma aban­doned in­fec­tious dis­eases, 5 biotech con­trar­i­ans de­cid­ed to go all in. Then Covid-19 changed every­thing

5 years ago
Coronavirus
In Focus

Turn­ing can­cer in­to a cur­able dis­ease: Im­munother­a­py ex­pert John Con­nol­ly picks up the reins as the new CSO of Sean Park­er’s can­cer in­sti­tute

5 years ago
Peer Review

A wob­bly Bio­gen makes a sur­prise switch in the ex­ec­u­tive suite, trig­ger­ing a re­newed burst of M&A chat­ter

5 years ago

Ex-Sanofi Gen­zyme chief David Meek­er hops to a new biotech CEO post, this time fo­cus­ing on quick leap to com­mer­cial­iza­tion

5 years ago
R&D

GSK’s Shin­grix leader Guil­laume Pfe­fer has jumped on board Flag­ship to helm a biotech hy­brid as Afeyan’s lat­est CEO-part­ner

5 years ago

Who are the women blaz­ing trails in bio­phar­ma R&D and lead­ing the fight against Covid-19? Nom­i­nate them for End­points' spe­cial re­port

5 years ago
Editor's note

White House tries to dis­cred­it An­tho­ny Fau­ci — could he be on his way out?

5 years ago
Coronavirus

Stan­ford star on­col­o­gy sci­en­tist Ed En­gle­man helped cre­ate the im­munother­a­py field. Now he wants to shake up neu­rode­gen­er­a­tion R&D

5 years ago
Financing
Startups

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

5 years ago
Coronavirus

Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

5 years ago

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

5 years ago
R&D
Pharma

EMA nom­i­nates Emer Cooke as ex­ec­u­tive di­rec­tor to re­place Gui­do Rasi

5 years ago

Sang­amo splits the R from the D in a re­or­ga­ni­za­tion — and bids chief farewell

5 years ago
R&D

Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

5 years ago
Bioregnum
Opinion

With its cam­pus ex­pand­ing as gene ther­a­py booms, Alde­vron brings in a top ex­ec from a medtech gi­ant to steer the course

5 years ago
Cell/Gene Tx

Daniel O’Day snatch­es an­oth­er I/O com­pa­ny, buy­ing half of a pi­o­neer­ing can­cer drug dis­cov­er­er's biotech

5 years ago
Deals

Promi­nent Har­vard pro­fes­sor in the hunt for $100M to back his an­ti-ag­ing play

5 years ago
Financing

UP­DAT­ED Dew­point nabs ex-Sanofi CEO Brandi­court and Bay­er VC chief Eck­hardt for board

5 years ago

A pi­o­neer­ing im­muno-on­col­o­gy re­searcher heads back to Dana-Far­ber as Eli Lil­ly’s can­cer R&D group un­der­goes a wrench­ing change­up

5 years ago
R&D

Har­vard's Charles Lieber in­dict­ed for ly­ing to the feds, bring­ing US re­searcher­s' Chi­na ties back to the spot­light

5 years ago
China

Lean­ing on BD to re­vive weak pipeline, Lund­beck plans to cut up to 160 jobs in R&D re­struc­tur­ing

5 years ago
R&D

Mod­er­na’s new CFO took a cut in salary to jump to the mR­NA rev­o­lu­tion­ary. But then there’s the rest of the com­pen­sa­tion pack­age

5 years ago
First page Previous page 67686970717273 Next page Last page
A service from the Financial Times